Skip to content

Study · In vitro (cells) · 1985

2 results

Comparison of the effects of thymosin and other thymic factors on modulation of interleukin-2 production.

Zatz MM, Oliver J, Sztein MB, Skotnicki AB, Goldstein AL

Journal of biological response modifiers1 Aug 1985Cited by 3 (Europe PMC)

PMID3875692 (opens in a new tab)PepBankPUB-03875692
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cultured human peripheral blood leukocytes, the enhancement of interleukin-2 production by thymosin fraction 5 was not due to thymosin alpha‑1.

    In plain wordsIn human blood cells in the lab, thymosin alpha‑1 was not the part of thymosin fraction 5 that raised interleukin-2 production.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeIL-2 production by human PBL, role of thymosin alpha 1 in TF5 activity
    Study

    humann: not reported in source

    human peripheral blood mononuclear leukocytes with PHA
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This important biological activity of TF5 is not due to the presence of two previously well-characterized component peptides, thymosin alpha 1 and thymosin beta 4, but rather to a new, still to be identified component of TF5.
    1 context sentence
    Summary · context
    Thymosin fraction 5 (TF5) enhances interleukin-2 (IL-2) production by human peripheral blood mononuclear leukocytes (PBL) when cocultured in the presence of phytohemagglutinin (PHA).
  2. 02LabIn vitro (cells)Activity measurement

    The enhancement of IL-2 production by thymosin fraction 5 in human leukocytes is not due to thymosin beta‑4.

    In plain wordsIn cells, thymosin beta‑4 did not explain the rise in IL-2 production caused by thymosin fraction 5.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeEnhancement of PHA-induced IL-2 production
    Study

    humann: not reported in source

    Human peripheral blood mononuclear leukocytes
    Comparator
    Thymosin fraction 5
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This important biological activity of TF5 is not due to the presence of two previously well-characterized component peptides, thymosin alpha 1 and thymosin beta 4, but rather to a new, still to be identified component of TF5.
    1 context sentence
    Summary · context
    Thymosin fraction 5 (TF5) enhances interleukin-2 (IL-2) production by human peripheral blood mononuclear leukocytes (PBL) when cocultured in the presence of phytohemagglutinin (PHA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.